Apotex Receives FDA’s Drug Shortage Assistance Award
Apr 19, 2023Recognized for efforts in resolving shortage of varenicline tablets
Toronto, Ontario (April 19, 2023) - Apotex Inc. is pleased to announce that it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA) in recognition of the company’s substantial efforts to resolve a shortage of varenicline tablets.
When the US market experienced a shortage of 0.5 mg and 1 mg varenicline tablets, and in order to reduce the impact to patients from an ongoing recall, the FDA temporarily exercised regulatory flexibility and discretion with respect to Apotex’s importation of Health-Canada approved Apo-Varenicline tablets in the U.S. The award also recognizes the submission and ultimate approval of an abbreviated new drug application (ANDA) for varenicline tablets in the U.S. market.
“We’re proud to receive this important award from the FDA, and to be recognized for our commitment to public health” said Allan Oberman, President and Chief Executive Officer, Apotex. “Our flexible supply chain and North American manufacturing model helped ensure an uninterrupted supply of medicines and demonstrates our focus on increasing access to affordable, high quality products.”
This award recognizes the efforts of drug companies and manufacturers who have worked in cooperation with FDA, and have implemented strategies to help provide a steady supply of medically necessary drugs at a time when critical drug shortages pose a substantial public health threat – delaying, and in some cases even denying, critically needed care for patients. Working with drug companies and manufacturers like Apotex, the FDA helped prevent 317 drug shortages in 2021.
About Apotex Inc.
Apotex is a proudly Canadian-based, global health company that produces high-quality, affordable medicines for patients around the world. Apotex employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. It exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico, and India. For more information, visit www.apotex.com.
-30-
All media enquiries :
Jordan Berman
Vice-President, Global Corporate Affairs
Apotex Inc.
jberman@apotex.com
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.